One recent article disproved the theory that SGLT2i reduces the inflammatory marker levels, showing no significant effect on CRP, ESR, or fibrinogen levels after 6 months of treatment in a group of patients with CHF [20]. The gene discussed is CRP; the disease is congestive heart failure.